The study also demonstrated a dose range which the Company believes will restore normal KLK1 levels in CKD patients. It is noteworthy that the pharmacokinetic (PK) profile in CKD subjects after dosing was similar to the PK profile in healthy volunteers.

We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) based on that […]

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 24, 2020 ...

MINNEAPOLIS, Sept. 03, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 19) Abbott Laboratories (NYSE: ABT ) CareDx Inc (NASDAQ: ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its fourth quarter 2019 financial results will be released after the markets close on Monday, March 23rd. DiaMedica will host a live conference call on Tuesday, March 24th at 7:00 AM Central Time to discuss its business update and financial results.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and reported its financial results for the year ended December 31, 2019.

MINNEAPOLIS, Sept. 06, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 17th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, May 27, 2020. Management will be available to participate in one-on-one meetings. Meetings will take place virtually given the ongoing call for social distancing due to the Covid-19 pandemic. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...

MINNEAPOLIS, Aug. 12, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2020 financial results will be released after the markets close on Wednesday, May 13th. DiaMedica will host a live conference call on Thursday, May 14th at 7:00 AM Central Time to discuss its business update and financial results.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled "Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease" at the National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference. For information about the virtual event, visit: https://www.kidney.org/spring-clinical.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...

Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for neurological disorders and chronic kidney disease, announced today that DM199, a drug intended to restore KLK1 levels and the body’s natural ability to regulate blood flow and reduce inflammation after an acute ischemic stroke (AIS), met primary safety and tolerability endpoints in the ReMEDy phase II study. Further, no DM199-related serious adverse events were noted in the study. According to top-line phase II results, there was also a demonstrated therapeutic effect in participants who received tissue plasminogen activator (tPA) prior to enrollment, but not in participants receiving mechanical thrombectomy.

DiaMedica Therapeutics to Participate at 32nd Annual ROTH Conference on March 15-17, 2020

MINNEAPOLIS, Aug. 08, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Biotech stocks went on a roller coaster ride in the week ended March 20 amid the market-wide COVID-19 sell-off. Activity remained light amid the cancellation of many medical meetings.The COVID-19 treatment and vaccine development news flow was front and center, as biopharma and diagnostics companies scrambled to capitalize on the need presented by the pandemic.This news flow is likely to continue into the unfolding week, with companies already in the fray providing updates and new entrants making announcements.View more earnings on IBBRelated Link: 8 Biotechs With Coronavirus Vaccines In DevelopmentThe following are other catalysts that could move stocks in the biotech space: PDUFA Dates The FDA is scheduled to announced its verdict on Bristol-Myers Squibb Co's (NYSE: BMY) NDA for ozanimod as a treatment option for patients with relapsing forms of multiple sclerosis. (Wednesday)IntelGenx Technologies Corp. OTCMKTS: (IGXT)'s NDA for rizaport versafilm for the treatment of acute migraine is pending before the FDA, with the target action day fixed for Thursday. The company has faced three rejections for the investigational drug in the past.The FDA is also expected to rule on Rockwell Medical Inc's (NASDAQ: RMTI) sNDA for intravenous formulation of anemia drug Triferic. (Saturday)Earnings Monday * DiaMedica Therapeutics Inc (NASDAQ: DMAC) (after the close) * Tuesday * Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close) * OpGen Inc (NASDAQ: OPGN) (after the close) * Onconova Therapeutics Inc (NASDAQ: ONTX) (after the close)Wednesday * Viela Bio Inc (NASDAQ: VIE) (after the close) * Biocept Inc (NASDAQ: BIOC) (after the close) * OncoCyte Corp (NYSE: OCX) (after the close) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the close) * Eyenovia Inc (NASDAQ: EYEN) (after the close) * Exagen Inc (NASDAQ: XGN) (after the close)Thursday * Celsion Corporation (NASDAQ: CLSN (before the market open) * Entera Bio Ltd (NASDAQ: ENTX) (before the market open) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (before the market open) * IGM Biosciences Inc (NASDAQ: IGMS) (after the close) * NovaBay Pharmaceuticals, Inc. (NYSE: NBY) (after the close) * Vermillion, Inc. (NASDAQ: VRML) (after the close)Friday * TELA Bio Inc (NASDAQ: TELA) (before the market open) * Zyla Life Sciences (OTC: ZCOR) (before the market open)IPO Quiet Period Expiry Passage Bio Inc (NASDAQ: PASG)See more from Benzinga * The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today announced positive top-line results from ReMEDy, its Phase II study in acute ischemic stroke (AIS), as well as provided a business update and financial results for the three months ended March 31, 2020. DiaMedica will host a conference call with slides tomorrow, May 14, 2020, at 7:00 a.m. Central Time to discuss its ReMEDy top-line data, business update and first quarter financial results. In conjunction with this release, DiaMedica also issued today a separate more detailed release on the ReMEDy top-line data.